Elan's asset sale continued today with the sale of its 80 per cent stake in Athena Diagnostics for $82 million.
Elan, together with the other stockholders, sold the company to Behrman Capital for a total consideration of $122 million.
Since the start of its restructuring plan, Elan has raised around $650 million in cash or 41 per cent of the target $1.5 billion needed to pay debts due in the next two years.